Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3008889 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BACECPB2CPB1 | |
| SCHEMBL3008885 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BACECPB2CPB1 | |
| Benzene SCHEMBL29402026 | 0.99 | ACE (0.47) | ITGB3ITGA2BACECPB2CPB1 | |
| SCHEMBL3439706 | 0.89 | KLK5 (0.41) | CPB2 | |
| SCHEMBL9838791 | 0.89 | KLK5 (0.41) | CPB2 | |
| SCHEMBL31270648 | 0.89 | ACE (0.41) | ITGB3ITGA2BACECPB2CPB1 | |
| SCHEMBL12658360 | 0.89 | CTSS (0.40) | CPB2CPB1MAPK1 | |
| SCHEMBL30643155 | 0.89 | CTSS (0.40) | CPB2CPB1MAPK1 | |
| SCHEMBL10775312 | 0.89 | ACE (0.53) | ITGB3ITGA2BACEMAPK1PTPN1 | |
| SCHEMBL29398206 | 0.89 | MAPK1 (0.42) | ITGB3ITGA2BACECPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-10265325-B2 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment | NEURODYN LIFE SCIENCES INC. (CA) | 2019-04-23 | — | — | US | disclosed |
| US-20180008613-A1 | CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT | NEURODYN LIFE SCIENCES INC (CA) | 2018-01-11 | — | — | US | disclosed |
| US-9763953-B2 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment | NEURODYN LIFE SCIENCES INC. (CA) | 2017-09-19 | — | — | US | disclosed |
| US-9763953-B2 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment | NEURODYN LIFE SCIENCES INC. (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20130210808-A1 | CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT | GALANTOS PHARMA GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210808-A1 | CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT | GALANTOS PHARMA GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20090253654-A1 | CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT | GALANTOS PHARMA GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253654-A1 | CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT | GALANTOS PHARMA GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180008613-A1 | CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT | CHAT, SLC18A3, CHRNB2 | ITGB3 4723/4885ITGA2B 3766/4885ACE 360/4885 |
| US-10265325-B2 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment | CHAT, SLC18A3, CHRNB2 | ITGB3 4723/4885ITGA2B 3766/4885ACE 360/4885 |
| US-20090253654-A1 | CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT | ACHE, BCHE, COMT | ITGB3 3562/4885ITGA2B 3427/4885ACE 78/4885 |
| US-20130210808-A1 | CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT | ACHE, BCHE, COMT | ITGB3 3562/4885ITGA2B 3427/4885ACE 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.